Market Cap 24.47M
Revenue (ttm) 0.00
Net Income (ttm) -11.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 145,300
Avg Vol 128,502
Day's Range N/A - N/A
Shares Out 32.56M
Stochastic %K 15%
Beta 1.56
Analysts Strong Sell
Price Target $8.38

Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatmen...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 9 799 6183
Address:
Building B, 11 HaMenofim Street, Herzliya, Israel
AvidCapital
AvidCapital Jun. 10 at 4:28 AM
$NRSN $CYTK Billion Dollar Buyout?
0 · Reply
lev57
lev57 Jun. 9 at 4:14 PM
$NRSN Someone deliberately leads the trade down in small cycles in order to rake in profits on the decline. And today despite the positive message. He continues to do so. Let's unite and prevent this from him.
1 · Reply
focafoca99
focafoca99 Jun. 9 at 2:21 PM
$NRSN adds a Japanese patent grant for PrimeC’s novel composition.
0 · Reply
lev57
lev57 Jun. 9 at 1:46 PM
$NRSN https://neurosense.investorroom.com/2026-06-09-NeuroSense-Therapeutics-Receives-Japanese-Patent-Grant-for-PrimeC-Novel-Composition
0 · Reply
tiddyy
tiddyy Jun. 9 at 12:14 PM
$NRSN With a guaranteed delay in each one see you in 2028!
0 · Reply
Babilon1210
Babilon1210 Jun. 9 at 5:49 AM
$NRSN Recent Health Canada meeting. Alzheimer's readout still pending. Insider-led financing. Manufacturing scale-up. Ongoing Alzheimer's program updates with upcoming readout. That cluster of events...this is a monster preparing to eat.
1 · Reply
tiddyy
tiddyy Jun. 8 at 4:30 PM
$NRSN Really, and what do you think the result is, you know they got a minimum bid notification, why not release it and use the ATM? You think these mfs care about the shareholders or they are protecting when they can raise. Answer me honestly, what do you think.
0 · Reply
Stekli27
Stekli27 Jun. 8 at 4:28 PM
$NRSN Unfortunetely
0 · Reply
Speculator2
Speculator2 Jun. 8 at 3:50 PM
$NRSN Following today's filing, and to somehow also align with this post, I think we will very soon finally see the AD readouts. Today's filing may be the first domino in a sequence of announcements before June 24. https://www.linkedin.com/posts/alonbn_detecting-alzheimers-disease-sooner-can-ugcPost-7469552675366535168-oMri/
0 · Reply
tiddyy
tiddyy Jun. 8 at 3:20 PM
$NRSN Their minimum bid notification is in September, so they are fucked
0 · Reply
Latest News on NRSN
NeuroSense Therapeutics Slides: Corporate presentation

May 4, 2026, 7:00 AM EDT - 5 weeks ago

NeuroSense Therapeutics Slides: Corporate presentation


NeuroSense Announces Pricing of Insider-Led PIPE Financing

Apr 28, 2026, 2:30 PM EDT - 6 weeks ago

NeuroSense Announces Pricing of Insider-Led PIPE Financing


NeuroSense announces departure of Chief Medical Officer

2026-04-26T22:31:45.000Z - 6 weeks ago

NeuroSense announces departure of Chief Medical Officer


NeuroSense Therapeutics Slides: Corporate presentation

Apr 14, 2026, 7:00 AM EDT - 2 months ago

NeuroSense Therapeutics Slides: Corporate presentation


NeuroSense granted Brazilian patent covering PrimeC composition

2026-04-06T13:34:33.000Z - 2 months ago

NeuroSense granted Brazilian patent covering PrimeC composition


NeuroSense Granted Brazilian Patent Covering PrimeC Composition

Apr 6, 2026, 9:20 AM EDT - 2 months ago

NeuroSense Granted Brazilian Patent Covering PrimeC Composition


NeuroSense Therapeutics Annual report: Q4 2025

Mar 31, 2026, 9:30 AM EDT - 2 months ago

NeuroSense Therapeutics Annual report: Q4 2025


NeuroSense Therapeutics Earnings release: Q4 2025

Mar 31, 2026, 9:30 AM EDT - 2 months ago

NeuroSense Therapeutics Earnings release: Q4 2025


PrimeC New Data to Be Presented at AD/PD™ 2026 Conference

Mar 18, 2026, 8:00 AM EDT - 2 months ago

PrimeC New Data to Be Presented at AD/PD™ 2026 Conference


NeuroSense Therapeutics Slides: Corporate presentation

Mar 11, 2026, 7:00 AM EDT - 3 months ago

NeuroSense Therapeutics Slides: Corporate presentation


NeuroSense initiated with a Buy at Roth Capital

2026-03-10T08:30:39.000Z - 3 months ago

NeuroSense initiated with a Buy at Roth Capital


NeuroSense files $150M mixed securities shelf

2026-01-29T22:30:20.000Z - 4 months ago

NeuroSense files $150M mixed securities shelf


NeuroSense Therapeutics Slides: Corporate presentation

Jan 4, 2026, 7:00 AM EST - 5 months ago

NeuroSense Therapeutics Slides: Corporate presentation


NeuroSense Therapeutics Slides: Corporate Presentation

Dec 9, 2025, 7:00 AM EST - 6 months ago

NeuroSense Therapeutics Slides: Corporate Presentation


NeuroSense Therapeutics Transcript: Status Update

Dec 8, 2025, 8:30 AM EST - 6 months ago

NeuroSense Therapeutics Transcript: Status Update


NeuroSense to Host Investor Webinar on December 8, 2025

Nov 3, 2025, 9:15 AM EST - 7 months ago

NeuroSense to Host Investor Webinar on December 8, 2025


NeuroSense files to sell 333K ordinary shares for holders

2025-10-28T20:36:43.000Z - 8 months ago

NeuroSense files to sell 333K ordinary shares for holders


NeuroSense initiated with an Outperform at Noble Capital

2025-10-14T13:35:14.000Z - 8 months ago

NeuroSense initiated with an Outperform at Noble Capital


NeuroSense Therapeutics Earnings release: Q2 2025

Jul 31, 2025, 6:00 PM EDT - 11 months ago

NeuroSense Therapeutics Earnings release: Q2 2025


NeuroSense initiated with a Buy at D. Boral Capital

2025-05-12T11:30:59.000Z - 1 year ago

NeuroSense initiated with a Buy at D. Boral Capital


NeuroSense Therapeutics Earnings release: Q4 2024

Apr 7, 2025, 4:00 PM EDT - 1 year ago

NeuroSense Therapeutics Earnings release: Q4 2024


NeuroSense Therapeutics Annual report: Q4 2024

Apr 7, 2025, 4:00 PM EDT - 1 year ago

NeuroSense Therapeutics Annual report: Q4 2024


NeuroSense regains Nasdaq compliance

2025-01-06T14:11:26.000Z - 1 year ago

NeuroSense regains Nasdaq compliance


NeuroSense files to sell 5.28M ordinary shares for holders

2024-12-26T21:55:04.000Z - 1 year ago

NeuroSense files to sell 5.28M ordinary shares for holders


NeuroSense Therapeutics Earnings release: Q3 2024

Dec 18, 2024, 8:00 AM EST - 1 year ago

NeuroSense Therapeutics Earnings release: Q3 2024


AvidCapital
AvidCapital Jun. 10 at 4:28 AM
$NRSN $CYTK Billion Dollar Buyout?
0 · Reply
lev57
lev57 Jun. 9 at 4:14 PM
$NRSN Someone deliberately leads the trade down in small cycles in order to rake in profits on the decline. And today despite the positive message. He continues to do so. Let's unite and prevent this from him.
1 · Reply
focafoca99
focafoca99 Jun. 9 at 2:21 PM
$NRSN adds a Japanese patent grant for PrimeC’s novel composition.
0 · Reply
lev57
lev57 Jun. 9 at 1:46 PM
$NRSN https://neurosense.investorroom.com/2026-06-09-NeuroSense-Therapeutics-Receives-Japanese-Patent-Grant-for-PrimeC-Novel-Composition
0 · Reply
tiddyy
tiddyy Jun. 9 at 12:14 PM
$NRSN With a guaranteed delay in each one see you in 2028!
0 · Reply
Babilon1210
Babilon1210 Jun. 9 at 5:49 AM
$NRSN Recent Health Canada meeting. Alzheimer's readout still pending. Insider-led financing. Manufacturing scale-up. Ongoing Alzheimer's program updates with upcoming readout. That cluster of events...this is a monster preparing to eat.
1 · Reply
tiddyy
tiddyy Jun. 8 at 4:30 PM
$NRSN Really, and what do you think the result is, you know they got a minimum bid notification, why not release it and use the ATM? You think these mfs care about the shareholders or they are protecting when they can raise. Answer me honestly, what do you think.
0 · Reply
Stekli27
Stekli27 Jun. 8 at 4:28 PM
$NRSN Unfortunetely
0 · Reply
Speculator2
Speculator2 Jun. 8 at 3:50 PM
$NRSN Following today's filing, and to somehow also align with this post, I think we will very soon finally see the AD readouts. Today's filing may be the first domino in a sequence of announcements before June 24. https://www.linkedin.com/posts/alonbn_detecting-alzheimers-disease-sooner-can-ugcPost-7469552675366535168-oMri/
0 · Reply
tiddyy
tiddyy Jun. 8 at 3:20 PM
$NRSN Their minimum bid notification is in September, so they are fucked
0 · Reply
IrishSean
IrishSean Jun. 8 at 3:01 PM
$NRSN So Q3 is when the Canadian question is answered. The cash runs out July I reckon. So either partnership or financing or bust. They need a bridge until Q3 Canadian decision, a coin flip. Plus previous catalyst was the Canadian decision to get a partner on board. Throws that thesis into question. They need a cash injection.
0 · Reply
Speculator2
Speculator2 Jun. 8 at 2:59 PM
$NRSN https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=320115554&type=HTML&symbol=NRSN&cdn=e1e8fda9914598f1d9ddc31f4df16c5d&companyName=NeuroSense+Therapeutics+Ltd.&formType=6-K&formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&dateFiled=2026-06-08
0 · Reply
KoalaFlipper
KoalaFlipper Jun. 8 at 2:09 PM
$NRSN NeuroSense (NRSN) advances Health Canada discussions on PrimeC ALS regulatory path. NeuroSense Therapeutics reports a regulatory milestone for its ALS drug candidate PrimeC. The company recently held a constructive meeting with Health Canada to discuss potential regulatory pathways supporting a New Drug Submission (NDS) for treating amyotrophic lateral sclerosis. NeuroSense presented additional clinical, biomarker, and long-term outcome data as previously requested by Health Canada, and outlined its proposed NDS strategy. The company expects an official response from Health Canada in the third quarter this year and plans to provide further updates on the Canadian regulatory process. https://www.stocktitan.net/sec-filings/NRSN/6-k-neuro-sense-therapeutics-ltd-current-report-foreign-issuer-1823eca72b19
0 · Reply
tiddyy
tiddyy Jun. 8 at 12:53 PM
$NRSN They forgot to update this relic, still shows Phase 3 First Patient In Q1 2026, and AD readout in Q1 2026 https://www.neurosense-tx.com/pipeline/ If only they were as active in recruiting patients in getting random participants for their on call June 24th
0 · Reply
tiddyy
tiddyy Jun. 4 at 5:40 PM
$NRSN When will this end.
0 · Reply
rml360
rml360 Jun. 4 at 4:21 PM
$NRSN I am going to assume that Canada is a no go, I would think a PR would have went out by now if they were going to file, I am sure there will be more BS on the call in two weeks
2 · Reply
tiddyy
tiddyy Jun. 3 at 4:18 PM
$NRSN With the current marketcap, and potential conservative annual sales of $500 million from PrimeC, currently the market is pricing this at a 97% failure.
2 · Reply
KoalaFlipper
KoalaFlipper Jun. 2 at 2:02 PM
$NRSN a stock always have to fall before it can rise to the skys.
0 · Reply
Speculator2
Speculator2 Jun. 2 at 2:00 PM
$NRSN ATM at work this morning - they are so low on cash they need to dump new shares at these extremely low levels. And no news on PIPE closure, no news on meeting with the regulators in Canada, no news on Alzheimer AD initially scheduled for Q1, and we have in the last month of Q2. Either something is cooking with all announcements together, or they are in final discussions for a major funding, or they have nothing positive to report. I tend to believe there is some positives with the silence or why would they schedule a call with now over 1100 attendees for later this month. I don't think they did it to ridicule themselves, but we need to see some positive materialization before, hopefully good minutes from Canada in a few weeks.
0 · Reply
tiddyy
tiddyy Jun. 1 at 5:41 PM
$NRSN One quarter left for them to somehow pump this to $1 or they gonna reverse split With the term sheet over, and the Phase 3 trial being delayed again, they will be lucky if this stays at $0.80 cent when September comes
0 · Reply
Aromadz
Aromadz May. 28 at 8:01 PM
$NRSN it got hammered late hours. not looking very good!
1 · Reply
rml360
rml360 May. 28 at 2:57 PM
$NRSN they presented in front of a half classroom of kids
2 · Reply